Loading organizations...
§ Private Profile · Lexington, MA, USA
T2 Biosystems is a technology company.
T2 Biosystems develops direct detection products for diagnostics, specializing in sepsis-causing pathogens and antibiotic resistance genes. Its proprietary T2 Magnetic Resonance (T2MR) platform directly detects targets from unpurified whole blood within hours. This technology delivers rapid, precise diagnostic insights, far faster than traditional culture-based methods.
Founded in 2006 by Lee Josephson, Michael Cima, and Tyler Jacks, T2 Biosystems addressed the critical need for expedited, accurate infectious disease diagnostics. The founders leveraged magnetic resonance technology to overcome conventional test delays in time-sensitive conditions. Their objective was to establish a new standard for pathogen identification.
The company's products serve hospitals and clinicians, providing critical data for managing severe infections like sepsis. T2 Biosystems’ long-term vision is to transform patient outcomes through timely diagnostic solutions. It aims to reduce healthcare costs and mitigate antimicrobial resistance via early detection, setting a new benchmark for rapid pathogen identification.
T2 Biosystems has raised $110.0M across 6 funding rounds.
T2 Biosystems has raised $110.0M in total across 6 funding rounds.
T2 Biosystems (NASDAQ: TTOO) is a medical technology company developing rapid diagnostic products for sepsis-causing pathogens and antibiotic resistance, using proprietary T2 Magnetic Resonance (T2MR) technology to detect infections directly from blood in 3-5 hours.[1][2][4] Its core products include the T2Dx Instrument platform, T2Bacteria Panel (detects 5+ bacterial pathogens), T2Candida Panel (identifies Candida species), T2Resistance Panel, and emerging tests like T2Lyme and T2Biothreat, serving hospitals, clinical labs, and research institutions to reduce diagnosis time from days to hours, improve patient outcomes, lower mortality, and cut healthcare costs.[1][2][4][5] The company targets sepsis—a leading hospital killer—with recent growth via FDA clearances for expanded panels, exclusive U.S. distribution with Cardinal Health, and partnerships like CARB-X and Prxcision for AI integration.[4][5][6]
Founded in 2006 and incorporated in Delaware, T2 Biosystems emerged from Flagship Pioneering to address unmet needs in rapid diagnostics, starting with sepsis detection using innovative T2MR technology that identifies pathogens without culturing.[1][2] Headquartered in Lexington, Massachusetts, the company built early traction through products like the T2Dx Instrument and panels for bacteria and Candida, gaining FDA clearances and CE Mark for Europe in 2017.[2][4] Pivotal moments include partnerships with CARB-X for resistance gene tests, studies validating Lyme detection in blood, and leadership hires like CFO Darlene Deptula-Hicks, evolving from R&D focus (e.g., $22.1M expenses in 2023 with ~90 employees) to commercialization amid a ~$16-20M market cap as of early 2024.[1][2][5]
T2 Biosystems rides the sepsis and antimicrobial resistance (AMR) crisis, where delayed diagnosis contributes to 11M annual global deaths and escalating hospital costs, amplified by post-COVID infection surges.[4][5] Timing aligns with FDA priorities for rapid diagnostics and U.S. government initiatives like BARDA/ASPR funding via CARB-X, positioning T2 to influence precision medicine by enabling faster, targeted therapies over broad-spectrum antibiotics.[5] In the medtech ecosystem, it counters AMR through direct detection, supports antibiotic trials, and integrates with AI platforms, fostering hospital efficiency amid trends like value-based care and biothreat preparedness.[4][5][6]
T2 Biosystems is poised for acceleration in 2025 with pipeline advancements (e.g., T2Resistance commercialization, Lyme panel), strengthened distribution via Cardinal/Vizient, and AI synergies to drive product sales amid AMR urgency.[4][6] Rising sepsis prevalence, regulatory tailwinds, and cost-saving proofs will shape growth, potentially expanding influence in global diagnostics if execution scales beyond current microcap status. This rapid-detection pioneer could redefine sepsis care, tying back to its mission of saving lives through faster, smarter treatment.[1][3][4]
T2 Biosystems has raised $110.0M across 6 funding rounds. Most recently, it raised $15.0M Other Equity in February 2024.
T2 Biosystems has raised $110.0M in total across 6 funding rounds.
T2 Biosystems's investors include CRG, Thomas Carella, Aisling Capital, Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Versant Ventures, Jason Henrichs, Arcus Ventures.